GLP-1 drugs show emerging benefits in NASH, Alzheimer's, cancer, infertility, and associative learning | Research

The takeaway

Beyond diabetes and obesity, GLP-1 receptor agonists demonstrate benefits in hypertension, dyslipidemia, NASH, Alzheimer's disease, and show emerging potential in cancer, infertility, and associative learning, with reduced major cardiovascular events.

Beyond diabetes: 5+ new indications
GLP-1 drugs show benefits in NASH, Alzheimer's, cancer, infertility, and learning beyond established diabetes, obesity, and cardiovascular applications

What the researchers found

Established: glycemic control, weight loss, CV event reduction, hypertension, dyslipidemia. Emerging: NASH, Alzheimer's, cancer (certain types), infertility, associative learning. Pipeline: insulin icodec (weekly), IcoSema (weekly insulin+semaglutide).

Why it matters

Clinicians prescribing GLP-1 drugs need to understand their full benefit profile to maximize patient care. This comprehensive overview covers both established and emerging applications.

How the study worked

Narrative review of GLP-1RA applications beyond diabetes across multiple therapeutic areas.

What this study cannot tell us

Review of varying evidence quality. Some applications based on preliminary data. Not all emerging indications will be validated.

How to read the evidence

Narrative review. Evidence ranges from robust (CVD, weight) to tenuous (learning, infertility).

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs may become the most versatile medication class in history, with applications spanning endocrinology, cardiology, neurology, hepatology, oncology, and reproductive medicine.

Questions still open

Which emerging indications will reach regulatory approval first?
Should GLP-1 drugs be prescribed for non-diabetic conditions now?
How will cost affect access to these expanding indications?

Common questions

What else can GLP-1 drugs treat besides diabetes?

Beyond diabetes and weight loss, GLP-1 drugs show benefits for: fatty liver disease (NASH), cardiovascular events, hypertension, high cholesterol, and emerging evidence in Alzheimer's disease, certain cancers, infertility, and even memory/learning. Not all of these are yet approved uses.

Will GLP-1 drugs be prescribed for brain diseases?

Possibly. The strongest neurological evidence is for Alzheimer's disease, where GLP-1 drugs show neuroprotective effects. Clinical trials are underway. It may be years before formal approval, but the biological rationale is strong.

Read the original research

Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.

Journal of clinical medicine, 14(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Sundararaman, Lalitha; Gouda, Divakara; Kumar, Anil; Sundararaman, Sumithra; Goudra, Basavana. (2025). Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss.. Journal of clinical medicine, 14(6). https://doi.org/10.3390/jcm14061978